IP International Journal of Orthopaedic Rheumatology

Interleukin-6 blocker for successful outcome of late-onset rheumatoid oligoarthritis

Full Text PDF

Author Details: Yuva Vishalini Ravindran, Subramanian Nallasivan

Volume : 3

Issue : 1

Online ISSN : 2581-9151

Print ISSN : 2581-8112

Article First Page : 35

Article End Page : 36


Newer cytokine therapies have revolutionised the management of Rheumatoid arthritis. Atypical oligoarthritis can also be a manifestation of RA and CCP antibodies have been proven to be most specific for Rheumatoid. Our patient had 2 years of painful ankle bilaterally and suggested for joint replacement due to osteoarthritis changes. After the diagnosis of RA using Anti-CCP antibodies, we elected to give Tocilizumab(IL 6 Blocker) which had made the patient to walk without wheelchair after 2 years. This suggests early appropriate diagnosis is the key and Biologics- the new Kid in the market- has proven to be effective in early Rheumatoid arthritis.

Tocilizumab, Oligoarthitis, IL-6 blocker, Anti-CCP antibodies, Rheumatoid arthritis

Doi No:-10.18231